{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:12:35Z","timestamp":1785424355915,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.idnow.2021.12.005","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T22:15:47Z","timestamp":1639606547000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["COPEDOL: A two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen"],"prefix":"10.1016","volume":"52","author":[{"given":"R.","family":"Landman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kousignian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Finkielsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Roustand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nachbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10148","key":"10.1016\/j.idnow.2021.12.005_bib0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","article-title":"HIV","volume":"392","author":"Ghosn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2021.12.005_bib0060","first-page":"93547","article-title":"Dolutegravir \u2013 a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"7","author":"Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.idnow.2021.12.005_bib0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"issue":"9893","key":"10.1016\/j.idnow.2021.12.005_bib0070","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.idnow.2021.12.005_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idnow.2021.12.005_bib0080","series-title":"HIV-1 genotypic drug resistance interpretation's algorithms","year":"2020"},{"issue":"1","key":"10.1016\/j.idnow.2021.12.005_bib0085","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idnow.2021.12.005_bib0090","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0000000000002533","article-title":"Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients","volume":"34","author":"Nasreddine","year":"2020","journal-title":"AIDS"},{"issue":"Suppl 4","key":"10.1016\/j.idnow.2021.12.005_bib0095","first-page":"18398","article-title":"Observational study on HIV-1-infected patients treated with an ARV combination therapy including raltegravir: the RACING cohort results at month 12","volume":"15","author":"Pugliese","year":"2012","journal-title":"J Int AIDS Soc"},{"issue":"4 Suppl 3","key":"10.1016\/j.idnow.2021.12.005_bib0100","doi-asserted-by":"crossref","first-page":"19780","DOI":"10.7448\/IAS.17.4.19780","article-title":"Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort","volume":"17","author":"Allavena","year":"2014","journal-title":"J Int AIDS Soc"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991921005509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991921005509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:30:27Z","timestamp":1763019027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991921005509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666991921005509"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2021.12.005","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COPEDOL: A two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}